Dr. Strosberg on Understanding the Current Field of Neuroendocrine Tumors

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).

After years of everolimus (Afinitor) and metastin analogs, the field is in a stage of expansion, says Strosberg. Agents such as telotristat ethyl (Xermelo) are signifying that new drugs—although niche—are signaling advancement in the treatment of NETs.